| Jennifer M Delgado, | |
|
53 Calle Barcelo, Barranquitas, PR 00794-1735 | |
| (787) 857-2688 | |
| Not Available |
| Full Name | Jennifer M Delgado |
|---|---|
| Gender | Female |
| Speciality | Obstetrics & Gynecology |
| Location | 53 Calle Barcelo, Barranquitas, Puerto Rico |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1538366893 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 18111 (Puerto Rico) | Primary |
| Entity Name | Salud Integral En La Montana Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275556946 PECOS PAC ID: 8527972827 Enrollment ID: O20040605000314 |
News Archive
Angiochem, Inc., a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier through LRP targeting, announced today that preclinical data on two of its oncology programs, ANG1005 and ANG1007, for the treatment of brain cancers, as well as data demonstrating the utility of Angiochem's EPiC platform to achieve efficient penetration rates in the brain and in cancer tumor tissue, will be highlighted at the 101st Annual meeting of the American Association for Cancer Research 2010.
Agendia, a world leader in molecular cancer diagnostics, announced today that company CEO Dr. Bernhard Sixt will provide testimony at a public meeting on July 20 in Washington D.C. on the federal regulation of laboratory developed tests (LDTs).
Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA (aflibercept) Injection for the treatment of diabetic retinopathy in patients with diabetic macular edema (DME). In 2014, the FDA granted EYLEA Breakthrough Therapy designation and Priority Review for the treatment of diabetic retinopathy in patients with DME.
Celsion Corporation announced today the Company's DIGNITY clinical trial evaluating the use of ThermoDox in combination with hyperthermia for the treatment of Recurrent Chest Wall (RCW) Breast Cancer was aired during commercial breaks on Good Morning America and CBS Sunday Morning this past weekend.
› Verified 8 days ago
| Entity Name | Salud Integral En La Montana Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487677159 PECOS PAC ID: 8527972827 Enrollment ID: O20040721000677 |
News Archive
Angiochem, Inc., a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier through LRP targeting, announced today that preclinical data on two of its oncology programs, ANG1005 and ANG1007, for the treatment of brain cancers, as well as data demonstrating the utility of Angiochem's EPiC platform to achieve efficient penetration rates in the brain and in cancer tumor tissue, will be highlighted at the 101st Annual meeting of the American Association for Cancer Research 2010.
Agendia, a world leader in molecular cancer diagnostics, announced today that company CEO Dr. Bernhard Sixt will provide testimony at a public meeting on July 20 in Washington D.C. on the federal regulation of laboratory developed tests (LDTs).
Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA (aflibercept) Injection for the treatment of diabetic retinopathy in patients with diabetic macular edema (DME). In 2014, the FDA granted EYLEA Breakthrough Therapy designation and Priority Review for the treatment of diabetic retinopathy in patients with DME.
Celsion Corporation announced today the Company's DIGNITY clinical trial evaluating the use of ThermoDox in combination with hyperthermia for the treatment of Recurrent Chest Wall (RCW) Breast Cancer was aired during commercial breaks on Good Morning America and CBS Sunday Morning this past weekend.
› Verified 8 days ago
| Entity Name | Salud Integral En La Montana Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184647851 PECOS PAC ID: 8527972827 Enrollment ID: O20040729001210 |
News Archive
Angiochem, Inc., a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier through LRP targeting, announced today that preclinical data on two of its oncology programs, ANG1005 and ANG1007, for the treatment of brain cancers, as well as data demonstrating the utility of Angiochem's EPiC platform to achieve efficient penetration rates in the brain and in cancer tumor tissue, will be highlighted at the 101st Annual meeting of the American Association for Cancer Research 2010.
Agendia, a world leader in molecular cancer diagnostics, announced today that company CEO Dr. Bernhard Sixt will provide testimony at a public meeting on July 20 in Washington D.C. on the federal regulation of laboratory developed tests (LDTs).
Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA (aflibercept) Injection for the treatment of diabetic retinopathy in patients with diabetic macular edema (DME). In 2014, the FDA granted EYLEA Breakthrough Therapy designation and Priority Review for the treatment of diabetic retinopathy in patients with DME.
Celsion Corporation announced today the Company's DIGNITY clinical trial evaluating the use of ThermoDox in combination with hyperthermia for the treatment of Recurrent Chest Wall (RCW) Breast Cancer was aired during commercial breaks on Good Morning America and CBS Sunday Morning this past weekend.
› Verified 8 days ago
| Entity Name | Salud Integral En La Montana Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578586244 PECOS PAC ID: 8527972827 Enrollment ID: O20040803000311 |
News Archive
Angiochem, Inc., a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier through LRP targeting, announced today that preclinical data on two of its oncology programs, ANG1005 and ANG1007, for the treatment of brain cancers, as well as data demonstrating the utility of Angiochem's EPiC platform to achieve efficient penetration rates in the brain and in cancer tumor tissue, will be highlighted at the 101st Annual meeting of the American Association for Cancer Research 2010.
Agendia, a world leader in molecular cancer diagnostics, announced today that company CEO Dr. Bernhard Sixt will provide testimony at a public meeting on July 20 in Washington D.C. on the federal regulation of laboratory developed tests (LDTs).
Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA (aflibercept) Injection for the treatment of diabetic retinopathy in patients with diabetic macular edema (DME). In 2014, the FDA granted EYLEA Breakthrough Therapy designation and Priority Review for the treatment of diabetic retinopathy in patients with DME.
Celsion Corporation announced today the Company's DIGNITY clinical trial evaluating the use of ThermoDox in combination with hyperthermia for the treatment of Recurrent Chest Wall (RCW) Breast Cancer was aired during commercial breaks on Good Morning America and CBS Sunday Morning this past weekend.
› Verified 8 days ago
| Entity Name | Salud Integral En La Montana Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316970833 PECOS PAC ID: 8527972827 Enrollment ID: O20040806000074 |
News Archive
Angiochem, Inc., a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier through LRP targeting, announced today that preclinical data on two of its oncology programs, ANG1005 and ANG1007, for the treatment of brain cancers, as well as data demonstrating the utility of Angiochem's EPiC platform to achieve efficient penetration rates in the brain and in cancer tumor tissue, will be highlighted at the 101st Annual meeting of the American Association for Cancer Research 2010.
Agendia, a world leader in molecular cancer diagnostics, announced today that company CEO Dr. Bernhard Sixt will provide testimony at a public meeting on July 20 in Washington D.C. on the federal regulation of laboratory developed tests (LDTs).
Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA (aflibercept) Injection for the treatment of diabetic retinopathy in patients with diabetic macular edema (DME). In 2014, the FDA granted EYLEA Breakthrough Therapy designation and Priority Review for the treatment of diabetic retinopathy in patients with DME.
Celsion Corporation announced today the Company's DIGNITY clinical trial evaluating the use of ThermoDox in combination with hyperthermia for the treatment of Recurrent Chest Wall (RCW) Breast Cancer was aired during commercial breaks on Good Morning America and CBS Sunday Morning this past weekend.
› Verified 8 days ago
| Entity Name | Salud Integral En La Montana Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639372618 PECOS PAC ID: 8527972827 Enrollment ID: O20160122000568 |
News Archive
Angiochem, Inc., a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier through LRP targeting, announced today that preclinical data on two of its oncology programs, ANG1005 and ANG1007, for the treatment of brain cancers, as well as data demonstrating the utility of Angiochem's EPiC platform to achieve efficient penetration rates in the brain and in cancer tumor tissue, will be highlighted at the 101st Annual meeting of the American Association for Cancer Research 2010.
Agendia, a world leader in molecular cancer diagnostics, announced today that company CEO Dr. Bernhard Sixt will provide testimony at a public meeting on July 20 in Washington D.C. on the federal regulation of laboratory developed tests (LDTs).
Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA (aflibercept) Injection for the treatment of diabetic retinopathy in patients with diabetic macular edema (DME). In 2014, the FDA granted EYLEA Breakthrough Therapy designation and Priority Review for the treatment of diabetic retinopathy in patients with DME.
Celsion Corporation announced today the Company's DIGNITY clinical trial evaluating the use of ThermoDox in combination with hyperthermia for the treatment of Recurrent Chest Wall (RCW) Breast Cancer was aired during commercial breaks on Good Morning America and CBS Sunday Morning this past weekend.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jennifer M Delgado, Po Box 360264, Center Medical Udh Adult 2, San Juan, PR 00936-0264 Ph: (787) 869-5900 | Jennifer M Delgado, 53 Calle Barcelo, Barranquitas, PR 00794-1735 Ph: (787) 857-2688 |
News Archive
Angiochem, Inc., a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier through LRP targeting, announced today that preclinical data on two of its oncology programs, ANG1005 and ANG1007, for the treatment of brain cancers, as well as data demonstrating the utility of Angiochem's EPiC platform to achieve efficient penetration rates in the brain and in cancer tumor tissue, will be highlighted at the 101st Annual meeting of the American Association for Cancer Research 2010.
Agendia, a world leader in molecular cancer diagnostics, announced today that company CEO Dr. Bernhard Sixt will provide testimony at a public meeting on July 20 in Washington D.C. on the federal regulation of laboratory developed tests (LDTs).
Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA (aflibercept) Injection for the treatment of diabetic retinopathy in patients with diabetic macular edema (DME). In 2014, the FDA granted EYLEA Breakthrough Therapy designation and Priority Review for the treatment of diabetic retinopathy in patients with DME.
Celsion Corporation announced today the Company's DIGNITY clinical trial evaluating the use of ThermoDox in combination with hyperthermia for the treatment of Recurrent Chest Wall (RCW) Breast Cancer was aired during commercial breaks on Good Morning America and CBS Sunday Morning this past weekend.
› Verified 8 days ago